BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.
Lim SM, Schalm SS, Lee EJ, Park S, Conti C, Millet YA, Woessner R, Zhang Z, Tavera-Mendoza LE, Stevison F, Albayya F, Dineen TA, Hsieh J, Oh SY, Zalutskaya A, Rotow J, Goto K, Lee DH, Yun MR, Cho BC.
Lim SM, et al. Among authors: hsieh j.
Ther Adv Med Oncol. 2024 Oct 21;16:17588359241280689. doi: 10.1177/17588359241280689. eCollection 2024.
Ther Adv Med Oncol. 2024.
PMID: 39444426
Free PMC article.